ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Your daily dose of the clinical news you may have missed.

Individuals newly classified with obesity using the European framework were found to be overall sicker and at greater risk for mortality.

Obesity medicine expert Bonnet answers questions about the downsides of GLP-1 therapy for obesity management and how lifestyle medicine interventions will help.

Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.

The Danish study analyzed a nationwide cohort of 2.1 million children and found no association between aluminum exposure and allergic, autoimmune, or neurodevelopmental conditions.

Your daily dose of the clinical news you may have missed.

A new analysis of the CAHtalog phase 3 study showed approximately 95% of participants experienced either high glucocorticoid exposure or elevated androstenedione levels during treatment.

Monu Khanna, MD, discusses the benefits of behavioral strategies, including yoga, breathwork, and dancing, in reducing cardiovascular disease risk in patients with obesity.

GX-03 has proven effective in preclinical trials, reducing disease severity by more than 50% vs placebo. Data from the current study are expected by year end.